Skip to main content
SpringerLink
Log in

Afatinib

  • Chapter
  • First Online:
Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 211))

Abstract

Afatinib (BIBW 2992, US: GilotrifTM, other countries: Giotrif©) is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was approved by the FDA and the EMA for the treatment of adults with advanced, EGFR mutation-positive non-small-cell lung cancer. Further investigations for the treatment of many other tumors with afatinib, e.g., HNSCC and breast cancer, are ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Afatinib—Compound Summary for CID 10184653. National Center for Biotechnology Information (2017) PubChem Compound Database, CID = 10184653, https://pubchem.ncbi.nlm.nih.gov/compound/10184653. Accessed on 26 Nov 2017

  • Agus DB, Terlizzi E, Stopfer P, Amelsberg A, Gordon MS (2006) (Hg): a phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol 24(suppl)

    Google Scholar 

  • Aw DC-W, Tan EH, Chin TM, Lim HL, Lee HY, Soo RA (2017) Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia-Pac J Clin Oncol. https://doi.org/10.1111/ajco.12687

  • Bahleda R, Hollebecque A, Varga A, Gazzah A, Massard C, Deutsch E et al (2015) Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. Br J Cancer 113(10):1413–1420. https://doi.org/10.1038/bjc.2015.374

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Barron F, de la Torre-Vallejo M, Luna-Palencia RL, Cardona AF, Arrieta O (2016) The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opin Drug Saf 15(11):S.1563–1572. https://doi.org/10.1080/14740338.2016.1236910

  • Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EEW (2014) Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials 15:S.469. https://doi.org/10.1186/1745-6215-15-469

  • Chu QS, Sangha R, Hotte SJ, Sergenson G, Schnell D, Chand VK, Hirte HW (2014) A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Invest New Drugs 32(6):1226–1235. https://doi.org/10.1007/s10637-014-0139-9

    Article  PubMed  CAS  Google Scholar 

  • Cohen S (1983) The epidermal growth factor (EGF). Cancer 51(10):1787–1791

    Article  CAS  PubMed  Google Scholar 

  • Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM et al (2017) Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol 28(10):2526–2532. https://doi.org/10.1093/annonc/mdx344

    Article  PubMed  CAS  Google Scholar 

  • Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S et al (2015) Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol 16(16):1700–1710. https://doi.org/10.1016/S1470-2045(15)00373-3

    Article  PubMed  CAS  Google Scholar 

  • Dunn LA, Fury MG, Sherman EJ, Ho AA, Katabi N, Haque SS, Pfister DG (2017) Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. Head Neck 101:S.292. https://doi.org/10.1002/hed.24938

  • Eberl M, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K et al (2012) Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 4(3):218–233. https://doi.org/10.1002/emmm.201100201

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Fan Z, Baselga J, Masui H, Mendelsohn J (1993) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53(19):4637–4642

    PubMed  CAS  Google Scholar 

  • Gazzah A, Boni V, Soria J-C, Holgado E, Even C, Ould Kaci M et al (2015) Phase Ib study of afatinib plus standard-dose cetuximab in patients (pts) with advanced solid tumors. JCO 33(15_suppl):S.2536. https://doi.org/10.1200/jco.2015.33.15_suppl.2536

  • Geater SL, Xu C-R, Zhou C, Hu C-P, Feng J, Lu S et al (2015) Symptom and quality of life improvement in LUX-Lung 6: an open-label phase III study of afatinib versus cisplatin/gemcitabine in Asian patients with EGFR mutation-positive advanced non–small-cell lung cancer. J Thorac Oncol 10(6):883–889. https://doi.org/10.1097/JTO.0000000000000517

    Article  PubMed  CAS  Google Scholar 

  • Harbeck N, Huang C-S, Hurvitz S, Yeh D-C, Shao Z, Im S-A et al (2016) Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol 17(3):357–366. https://doi.org/10.1016/S1470-2045(15)00540-9

    Article  PubMed  CAS  Google Scholar 

  • Hirsh V (2015) Next-generation covalent irreversible kinase inhibitors in NSCLC: focus on afatinib. BioDrugs 29(3):167–183. https://doi.org/10.1007/s40259-015-0130-9

  • Hochmair M, Holzer S, Burghuber OC (2016) Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases. Anticancer Drugs 27(9):914–915. https://doi.org/10.1097/CAD.0000000000000410

    Article  PubMed  CAS  Google Scholar 

  • Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M et al (2015) Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)–pretreated non–small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 10(1):156–163. https://doi.org/10.1097/JTO.0000000000000380

    Article  PubMed  CAS  Google Scholar 

  • Ioannou N, Dalgleish AG, Seddon AM, Mackintosh D, Guertler U, Solca F, Modjtahedi H (2011) Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 105(10):1554–1562. https://doi.org/10.1038/bjc.2011.396

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM et al (2013) Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med: Off Publ Soc Nucl Med 54(6):936–943. https://doi.org/10.2967/jnumed.112.110239

    Article  CAS  Google Scholar 

  • Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A et al (2013) LUX-Lung 4: a phase II trial of afatinib in patients with advanced non–small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. JCO 31(27):3335–3341. https://doi.org/10.1200/JCO.2012.45.0981

    Article  CAS  Google Scholar 

  • Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141(7):1117–1134. https://doi.org/10.1016/j.cell.2010.06.011

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711. https://doi.org/10.1038/onc.2008.109

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Li S-H, Liu C-Y, Hsu P-C, Fang Y-F, Wang C-C, Kao K-C et al (2017) Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert Rev Anticancer Ther 18(1):81–89. https://doi.org/10.1080/14737140.2018.1409623

    Article  PubMed  CAS  Google Scholar 

  • Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T et al (2015) Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma. J Thorac Oncol 10(5):S.738–746. https://doi.org/10.1097/jto.0000000000000492

  • Machiels J-PH, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16(5):583–594. https://doi.org/10.1016/S1470-2045(15)70124-5

    Article  PubMed  CAS  Google Scholar 

  • Mao X, Chen Z, Zhao Y, Yu Y, Guan S, Woodfield SE et al (2017) Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Oncotarget 8(1):1555–1568. https://doi.org/10.18632/oncotarget.13657

    Article  PubMed  Google Scholar 

  • Miller VA, Hirsh V, Cadranel J, Chen Y-M, Park K, Kim S-W et al (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13(5):528–538. https://doi.org/10.1016/S1470-2045(12)70087-6

    Article  PubMed  CAS  Google Scholar 

  • Minkovsky N, Berezov A (2008) BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs (London, Engl: 2000) 9(12):S.1336–1346

    Google Scholar 

  • Modjtahedi H, Dean C (1994) The receptor for EGF and its ligands—expression, prognostic value and target for therapy in cancer (review). Int J Oncol 4(2):277–296

    PubMed  CAS  Google Scholar 

  • Modjtahedi H, Cho BC, Michel MC, Solca F (2014) A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg’s Arch Pharmacol 387(6):S.505–521. https://doi.org/10.1007/s00210-014-0967-3

  • Molife LR, Omlin A, Jones RJ, Karavasilis V, Bloomfield D, Lumsden G et al (2014) Randomized phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol 10(2):S.219–231. https://doi.org/10.2217/fon.13.250

  • Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N et al (2017) A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Lung Cancer (Amsterdam, Neth) 108:S.154–160. https://doi.org/10.1016/j.lungcan.2017.03.009

  • Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J et al (2015) Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. Cancer Chemother Pharmacol 76(4):739–750. https://doi.org/10.1007/s00280-015-2826-4

    Article  PubMed  CAS  Google Scholar 

  • Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y et al (2013) afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 12(5):589–597. https://doi.org/10.1158/1535-7163.MCT-12-0885

    Article  PubMed  CAS  Google Scholar 

  • Park K, Tan E-H, O’Byrne K, Zhang L, Boyer M, Mok T et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17(5):577–589. https://doi.org/10.1016/S1470-2045(16)30033-X

    Article  PubMed  CAS  Google Scholar 

  • Paz-Ares L, Tan E-H, O’Byrne K, Zhang L, Hirsh V, Boyer M et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28(2):270–277. https://doi.org/10.1093/annonc/mdw611

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Megalophonos VF, Kamsu-Kom N et al (2011) EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res 17(20):6522–6530. https://doi.org/10.1158/1078-0432.CCR-11-1607

    Article  PubMed  CAS  Google Scholar 

  • Quesnelle KM, Grandis JR (2011) Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 17(18):5935–5944. https://doi.org/10.1158/1078-0432.CCR-11-0370

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P et al (2014) Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/nou160

  • Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A et al (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest https://doi.org/10.1172/jci38746

  • Ring A, Wheatley D, Hatcher H, Laing R, Plummer R, Uttenreuther-Fischer M et al (2015) Phase I study to assess the combination of afatinib with trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 21(12):2737–2744. https://doi.org/10.1158/1078-0432.CCR-14-1812

    Article  CAS  Google Scholar 

  • Roskoski R (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74. https://doi.org/10.1016/j.phrs.2013.11.002

    Article  PubMed  CAS  Google Scholar 

  • Schuler M, Yang JC-H, Park K, Kim J-H, Bennouna J, Chen Y-M et al (2016) Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 27(3):417–423. https://doi.org/10.1093/annonc/mdv597

    Article  PubMed  CAS  Google Scholar 

  • Schütze C, Dörfler A, Eicheler W, Zips D, Hering S, Solca F et al (2007) Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 183(5):256–264. https://doi.org/10.1007/s00066-007-1696-z

    Article  PubMed  Google Scholar 

  • Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol: Off J Am Soc Clin Oncol 31(27):S.3327–3334. https://doi.org/10.1200/jco.2012.44.2806

  • Sigismund S, Avanzato D, Lanzetti L (2017) Emerging functions of the EGFR in cancer. Mol Oncol. https://doi.org/10.1002/1878-0261.12155

  • Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342–350. https://doi.org/10.1124/jpet.112.197756

    Article  PubMed  CAS  Google Scholar 

  • Soria J-C, Felip E, Cobo M, Lu S, Syrigos K, Lee KH et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16(8):897–907. https://doi.org/10.1016/S1470-2045(15)00006-6

    Article  PubMed  CAS  Google Scholar 

  • Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R et al (2015) A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 51(16):2275–2284. https://doi.org/10.1016/j.ejca.2015.07.041

    Article  PubMed  CAS  Google Scholar 

  • Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, Machiels J-P (2013) A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol: Off J Eur Soc Med Oncol 24(5):1392–1400. https://doi.org/10.1093/annonc/mds633

    Article  CAS  Google Scholar 

  • Wang S-Q, Liu S-T, Zhao B-X, Yang F-H, Wang Y-T, Liang Q-Y et al (2015) Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1. Oncotarget 6(28):26142–26160. https://doi.org/10.18632/oncotarget.4536

    Article  PubMed  PubMed Central  Google Scholar 

  • Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P (2017) Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet 56(3):235–250. https://doi.org/10.1007/s40262-016-0440-1

    Article  PubMed  CAS  Google Scholar 

  • Wong CH, Ma BBY, Hui CWC, Tao Q, Chan ATC (2015) Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC). Am J Cancer Res 5(12):S.3588–3599

    Google Scholar 

  • Wu Y-L, Zhou C, Hu C-P, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213–222. https://doi.org/10.1016/S1470-2045(13)70604-1

    Article  PubMed  CAS  Google Scholar 

  • Xue C, Tian Y, Zhang J, Zhao Y, Zhan J, Fang W, Zhang L (2016) In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma. Drug Des Dev Ther 10:1299–1306. https://doi.org/10.2147/DDDT.S94432

    Article  CAS  Google Scholar 

  • Yang JC-H, Shih J-Y, Su W-C, Hsia T-C, Tsai C-M, Ou S-HI et al (2012) Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 13(5):S.539–548. https://doi.org/10.1016/s1470-2045(12)70086-4

  • Yang JC-H, Hirsh V, Schuler M, Yamamoto N, O’Byrne KJ, Mok TSK et al (2013) Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. JCO 31(27):S.3342–3350. https://doi.org/10.1200/jco.2012.46.1764

  • Yang JC-H, Sequist LV, Geater SL, Tsai C-M, Mok TSK, Schuler M et al (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16(7):S.830–838. https://doi.org/10.1016/s1470-2045(15)00026-1

  • Yang JC-H, Wu Y-L, Schuler M, Sebastian M, Popat S, Yamamoto N et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):S.141–151. https://doi.org/10.1016/s1470-2045(14)71173-8

  • Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J (2017) Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis. Int J Cancer 140(12):2805–2819. https://doi.org/10.1002/ijc.30691

    Article  PubMed  CAS  Google Scholar 

  • Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H et al (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. JCO 28(25):3965–3972. https://doi.org/10.1200/JCO.2009.26.7278

    Article  CAS  Google Scholar 

  • Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI et al (2015) Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol 10(4):501–508. https://doi.org/10.1007/s11523-014-0353-6

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, and Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany

    Helga Wecker & Cornelius F. Waller

Authors
  1. Helga Wecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cornelius F. Waller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cornelius F. Waller .

Editor information

Editors and Affiliations

  1. MOLIT Institute, Cancer Center Heilbronn-Franken, SLK-Clinics, Heilbronn, Baden-Württemberg, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wecker, H., Waller, C.F. (2018). Afatinib. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 211. Springer, Cham. https://doi.org/10.1007/978-3-319-91442-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91442-8_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91441-1

  • Online ISBN: 978-3-319-91442-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation